AESOP

AESOP Technology develops the AESOP Clinical Deep Reasoning Engine, described by the company as a clinical decision intelligence system that reconstructs, models and analyzes how clinical decisions are made in real-world care settings. Rather than limiting itself to outcome prediction, the engine aims to capture the logic, context and evidence relationships behind decisions in diagnosis, treatment, medication management and medical coding, and to make that reasoning explainable and traceable. The company states the engine draws on 3.2 billion real-world health records, integrates multiple medical knowledge graphs, and processes both structured and unstructured clinical data including diagnoses, medications, laboratory tests, examinations, procedures, imaging reports and narrative documentation. From these records AESOP says it has extracted more than 5 million clinical decision logic pathways.

The product line includes DxPrime, an AI solution for diagnostic accuracy that performs real-time integrity analysis, tailors insights by specialty, gender and clinical context, automatically translates diagnoses into medical codes, supports surgical coding, and detects left-right laterality mismatches. RxPrime (previously named MedGuard) targets wrong-drug errors, including look-alike/sound-alike (LASA) medication confusions. Medigator, embedded directly into hospital electronic health records, loads U.S. National Comprehensive Cancer Network cancer-treatment guidelines, cross-checks them against patient data, and continuously scans journals and clinical-trial databases to surface relevant published evidence, with recommendations updated within hours of new findings. AESOP also offers analytics that assess how closely hospitals adhere to international guidelines and where real-world outcomes diverge, for use by tumor boards and research partners.

Founding story

AESOP originated in a long-term research project at Taipei Medical University led by Professor Yu-Chuan (Jack) Li, begun as a research project in 2011 with the goal of making medication safer. An early attempt to analyze the interaction of diseases and medications using 12 years of health insurance data covering roughly 7,000 diseases and 1,400 ICD-9-CM medications was estimated to require over 100 years of computation on National Center for High-Performance Computing resources; the team instead analyzed each dimension separately before cross-linking diseases and medications. To move the research into clinical products, Li recruited Dr. An-Jim (Jim) Long, a former student who became CIO of a TMU-affiliated hospital, and Dr. Jeremiah Scholl, a former TMU visiting assistant professor.

Business model

AESOP sells clinical decision support and coding software to healthcare providers, delivered through integration into hospital electronic health record workflows and distributed via platform marketplaces including the Epic App Market and Mayo Clinic Platform.

Software supplied to hospitals and health systems; the company reports that early hospital users of DxPrime saw a 5% increase in reimbursement per inpatient and fewer insurer denials, positioning the products around both clinical safety and revenue-cycle outcomes.

Traction

The company reports 3.2 billion medical records integrated from Taiwan's National Health Insurance data, U.S. Medicare, the Mayo Clinic and DARTNet, and over 5 million extracted clinical decision logic pathways. DxPrime is reported to have reached 100% user adoption in deployments, with early hospital users seeing a 5% increase in reimbursement per inpatient. Published evaluations covered 438,558 prescriptions from 44 physicians across 23 specialties and 125,000 patients at a regional teaching hospital (MedGuard alert rate 2.28%, diagnostic recommendation acceptance 56.55%), and a separate two-year study of 1,206,895 prescriptions with a 2.36% alert rate. DxPrime's qualification on Mayo Clinic Platform is described as making it available to support over 52,000 physicians across the Mayo Clinic Care Network.

Latest developments

In October 2025 DxPrime was announced as a qualified solution on Mayo Clinic Platform. In December 2025 the company announced ISO 27001 certification and completion of a SOC 2 examination. Scheduled activities include ViVE in Los Angeles (February 2026), a Rapid Innovation Pitch at PharmStars' Pharmatech Innovation Summit in Boston (May 2026), a research poster on automated identification of high-risk inflammatory bowel disease patients using multimodal EMR data at the Mayo Clinic 2026 AI Research Summit, and sessions at PlatforMed in June 2026.